Total
0
Shares
Biocannabix (TSXV:RLV) enters into LOI with IAM Health GmbH
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • The terms of the LOI allow Biocannabix to hold a 51 per cent equity interest of the combined entity and continued operations under the IAM Health GmbH name
  • The partnership between BCX and IAM was designed to provide continuity to the research it began in the pediatric cannabinoid space
  • Relevium is a publicly-traded company that operates in the health and wellness industry, including cannabinoids, with a primary focus on online distribution
  • Relevium Technologies Inc. (RLV) is up 20 per cent and is trading at C$0.030 at 3:35 pm ET

Relevium Technologies (RLV) and its subsidiary, Biocannabix Health Corporation, have entered into an LOI with IAM Health GmbH to pursue research opportunities.

The terms of the LOI will allow Biocannabix to hold a 51 per cent equity interest of the combined entity and continue operations under the IAM Health GmbH name. IAM Health GmbH will become the Biocannabix brand and driver for clinical and research therapeutics.

IAM Health GmbH was founded by a group of multi-disciplinary professionals, combining legal expertise, medical doctors, research and clinical development specialists, and contract manufacturing.

The intention is to research new treatments for autoimmune conditions, including a study of the role of certain cannabinoids, primarily for the development of therapies for pediatric applications.

The partnership between BCX and IAM will provide continuity to the research it began in the pediatric cannabinoid space and leverage its clinical and research capabilities. 

Aurelio Useche, CEO of Relevium stated,

"We are extremely pleased to enter into this valued partnership with IAM Health and their team, as we set a new direction for Biocannabix."

"The partnership in Germany will drive focus and solidify the company’s new direction for the development of proprietary consumer and medical products," added Useche.

Nina Wlodarczyk, Managing Director of IAM Health, commented,

“We have developed the ideal ecosystem for conducting research and clinical activities that can leverage not only our new infrastructure here in Germany but also the existing established relationships in Colombia."

Relevium is a publicly-traded company that operates in the health and wellness industry, including cannabinoids, with a primary focus on online distribution.

Based in Germany, IAM Health GmbH is a privately owned clinical and research company in the domains of nutraceuticals, and pharmaceuticals seeking partnerships for the development of innovative, patented nature sourced products.

Relevium Technologies Inc. (RLV) is up 20 per cent and is trading at C$0.030 at 3:35 pm ET.

More From The Market Herald
VitalHub - President and CEO, Dan Matlow - The Market Herald Canada

" VitalHub (TSXV:VHI) to commence trading on the TSX

VitalHub (VHI) begins trading on the Toronto Stock Exchange on September 23, 2021.
BetterLife Pharma - CEO, Ahmad Doroudian. - The Market Herald Canada

" BetterLife (CSE:BETR) enrolls first patient in Interferon alpha-2b COVID-19 trial

The first patient has been enrolled in BetterLife’s (BETR) Interferon alpha-2b COVID-19 trial in Chile.
International Consolidated Uranium (TSXV:CUR) partners with Mars Investor Relations

" Algernon Pharmaceuticals (CSE:AGN) welcomes Dr. Mark Williams to the board

Algernon Pharmaceuticals (AGN) is pleased to announce that Dr. Mark Williams has been appointed as a member of the Board of Directors.
Small Pharma - CEO, Peter Rands (third from left) and the Small Pharma team. - The Market Herald Canada

" Negev Capital doubles down on Small Pharma (TSXV:DMT)

Negev Capital, a psychedelic medical intervention fund, has doubled its investment in Small Pharma (DMT).